Intelligence · Clinical Development
Pipeline search results
Programs matching “antibody” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 75 pipeline programs matching "antibody" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
299AR301
Biogen
Kidney Transplant Recipients with Late Antibody-Mediated Rejection
1 trial -
APHP211057
Pari Pharma GmbH
myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
1 trial -
ARGX-113-2308
argenx
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
1 trial -
Anti-PD-1 antibody drug named Serplulimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Rectal Cancer (LARC)
1 trial -
Cinryze®
Takeda
Acute Antibody-Mediated Rejection (AMR)
1 trial -
Clazakizumab
CSL Behring GmbH
Antibody-mediated Rejection
1 trial -
Combined use of TPO-RAs with low-dose anti-CD20 antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia (ITP)
1 trial -
Fostamatinib disodium
RIGEL PHARMACEUTICALS INC
Warm Antibody Autoimmune Hemolytic Anemia
2 trials -
KT-US-679-0788
Lacuna Pharma Pty Ltd
Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
1 trial -
MOG001
Lacuna Pharma Pty Ltd
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)
1 trial -
NL79088.041.21
Disc Medicine
Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Rituximab
Hospital Authority, Hong Kong
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
1 trial -
WN43194
Hoffmann-La Roche
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
1 trial -
ziltivekimab, Ziltivekimab
NovoThirteen
The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction
1 trial -
ARGX-113-2302
argenx
Antibody-Mediated Rejection
1 trial -
Anti-CD38 antibody Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Antiphospholipid Syndrome
1 trial -
Anti-CD40 Agonist Monoclonal Antibody CDX-1140
United Therapeutics Europe Ltd
Ovarian Clear Cell Adenocarcinoma
1 trial -
Anti-PD-1 antibody
The First People's Hospital of Lianyungang
Chronic Hepatitis b
1 trial -
Anti-PD-1 antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
Anti-PD-1 antibody drug named Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stage IV HCC
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Primary Sclerosing Cholangitis
1 trial -
Antibody UB-421
United Therapeutics Europe Ltd
HIV-1 Infection in Adults
1 trial -
BCMA/CD3 bispecific antibody (CM336)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Solitary Bone Plasmacytoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.